On Tuesday, Denali Therapeutics Inc (NASDAQ: DNLI) opened higher 12.69% from the last session, before settling in for the closing price of $15.6. Price fluctuations for DNLI have ranged from $10.57 to $33.33 over the past 52 weeks.
A company in the Healthcare sector has dropped its sales by -4.46% annually for the last half of the decade. Company’s average yearly earnings per share was noted -16.95% at the time writing. With a float of $131.18 million, this company’s outstanding shares have now reached $146.63 million.
Denali Therapeutics Inc (DNLI) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Denali Therapeutics Inc is 10.55%, while institutional ownership is 94.20%. The most recent insider transaction that took place on Aug 12 ’25, was worth 39,884. In this transaction COFO and Secretary of this company sold 2,937 shares at a rate of $13.58, taking the stock ownership to the 242,346 shares. Before that another transaction happened on Aug 12 ’25, when Company’s Chief Medical Officer sold 2,937 for $13.58, making the entire transaction worth $39,884. This insider now owns 217,391 shares in total.
Denali Therapeutics Inc (DNLI) Latest Financial update
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.67 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.85) by 0.18. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.8 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -16.95% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.46% during the next five years compared to -4.46% drop over the previous five years of trading.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Check out the current performance indicators for Denali Therapeutics Inc (DNLI). In the past quarter, the stock posted a quick ratio of 9.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.91, a number that is poised to hit -0.75 in the next quarter and is forecasted to reach -2.89 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Let’s dig in a bit further. During the last 5-days, its volume was 1.69 million. That was better than the volume of 1.55 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 64.56%.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 97.28%, which indicates a significant decrease from 97.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.96 in the past 14 days, which was higher than the 0.77 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.13, while its 200-day Moving Average is $15.37. However, in the short run, Denali Therapeutics Inc’s stock first resistance to watch stands at $18.44. Second resistance stands at $19.31. The third major resistance level sits at $20.94. If the price goes on to break the first support level at $15.95, it is likely to go to the next support level at $14.32. The third support level lies at $13.45 if the price breaches the second support level.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
There are currently 146,662K shares outstanding in the company with a market cap of 2.58 billion. Presently, the company’s annual sales total 0 K according to its annual income of -422,770 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -126,900 K.
